Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.37 |
| ▸ | POLA1 | P09884 | 2/20 | 0.35 |
| ▸ | DNTT | P04053 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | PRKCA | P17252 | 5/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4478707 | 0.75 | POLA1 (0.33) | CYP4F2CYP4A11POLA1DNTTPOLB | |
| SCHEMBL18621596 | 0.75 | POLA1 (0.36) | CYP4F2CYP4A11POLA1DNTTPOLB | |
| SCHEMBL1908101 | 0.70 | SLC6A2 (0.35) | CYP1A2CYP3A4CYP2D6CYP2C19MEN1 | |
| SCHEMBL22064251 | 0.70 | CYP2D6 (0.36) | POLA1DNTTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL4814367 | 0.69 | AKT1 (0.44) | CYP4F2CYP4A11NAAA | |
| SCHEMBL4810968 | 0.68 | AKT1 (0.46) | CYP4F2CYP4A11NAAA | |
| SCHEMBL27566082 | 0.68 | EPHX2 (0.31) | POLA1ALDH1A1EPHX2 | |
| Hydrochloric Acid SCHEMBL27517255 | 0.67 | GNAI3 (0.33) | ALDH1A1EPHX2 | |
| SCHEMBL11029945 | 0.67 | SLC6A2 (0.37) | CYP2D6KDM4E | |
| SCHEMBL29265308 | 0.67 | POLA1 (0.37) | CYP4F2CYP4A11POLA1DNTTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210023049-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | DOV PHARMACEUTICAL, INC. | 2021-01-28 | — | — | US | disclosed |
| US-20190070148-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | DOV PHARMACEUTICAL, INC. | 2019-03-07 | — | — | US | disclosed |
| EP-2719384-B1 | Novel 1-naphthyl-3-azabicyclo[3.1.0]hexanes:preparation and use to treat neuropsychiatric disorders | OTSUKA AMERICA PHARMACEUTICAL INC (US) | 2018-08-08 | — | — | EP | disclosed |
| US-10039746-B2 | 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-20180000777-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | EUTHYMICS BIOSCIENCE, INC. | 2018-01-04 | — | — | US | disclosed |
| US-9737506-B2 | 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | NEUROVANCE, INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160158197-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | EUTHYMICS BIOSCIENCE, INC. | 2016-06-09 | — | — | US | disclosed |
| US-9205074-B2 | 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | NEUROVANCE, INC. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150148399-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | EUTHYMICS BIOSCIENCE, INC. | 2015-05-28 | — | — | US | disclosed |
| US-8877798-B2 | 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | NEUROVANCE, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| EP-2719384-A1 | Novel 1 -naphthyl-3-azabicyclo[3.1.0]hexanes:preparation and use to treat neurophychiatric disorders | Euthymic Bioscience, Inc. (US) | 2014-04-16 | — | — | EP | disclosed |
| US-20130345439-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2013-12-26 | — | — | US | disclosed |
| US-8461196-B2 | 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | DOV PHARMACEUTICAL | 2013-06-11 | — | — | US | disclosed |
| US-20120302619-A1 | Novel 1-aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2012-11-29 | — | — | US | disclosed |
| US-20090233978-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2009-09-17 | — | — | US | disclosed |
| EP-1874298-A4 | METHODS AND COMPOSITIONS FOR PRODUCTION, FORMULATION AND USE OF 1-ARYL-3-AZABICYCLO[3,1,0]HEXANES | DOV PHARMACEUTICAL INC (US) | 2009-08-05 | — | — | EP | disclosed |
| EP-1874298-A2 | METHODS AND COMPOSITIONS FOR PRODUCTION, FORMULATION AND USE OF 1-ARYL-3-AZABICYCLO[3,1,0]HEXANES | DOV Pharmaceutical Inc. (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20070082940-A1 | Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | OTSUKA AMERICA PHARMACEUTICAL, INC. | 2007-04-12 | — | — | US | disclosed |
| US-20060223875-A1 | Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3.1.0]hexanes | DOV PHARMACEUTICAL, INC. | 2006-10-05 | — | — | US | disclosed |
| WO-2006096810-A2 | METHODS AND COMPOSITIONS FOR PRODUCTION, FORMULATION AND USE OF 1-ARYL-3-AZABICYCLO[3.1.0] HEXANES | DOV PHARMACEUTICAL, INC. (US) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345439-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | CYP4F2 573/4885CYP4A11 171/4885POLA1 3794/4885 |
| US-20120302619-A1 | Novel 1-aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | CYP4F2 573/4885CYP4A11 171/4885POLA1 3794/4885 |
| US-10039746-B2 | 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | HTR3C, HTR1D, HTR1B | CYP4F2 530/4885CYP4A11 143/4885POLA1 3749/4885 |
| US-20070082940-A1 | Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders | HTR3C, HTR1B, HTR2C | CYP4F2 573/4885CYP4A11 171/4885POLA1 3794/4885 |
| US-20090233978-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | CYP4F2 573/4885CYP4A11 171/4885POLA1 3794/4885 |
| US-20180000777-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | CYP4F2 573/4885CYP4A11 171/4885POLA1 3794/4885 |
| US-20150148399-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | CYP4F2 573/4885CYP4A11 171/4885POLA1 3794/4885 |
| US-20190070148-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | CYP4F2 573/4885CYP4A11 171/4885POLA1 3794/4885 |
| US-20210023049-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | CYP4F2 573/4885CYP4A11 171/4885POLA1 3794/4885 |
| US-20060223875-A1 | Methods and compositions for production, formulation and use of 1-aryl-3-azabicyclo[3.1.0]hexanes | HTR1B, SLC6A3, CYP1B1 | CYP4F2 305/4885CYP4A11 329/4885POLA1 3199/4885 |
| US-20160158197-A1 | Novel 1-Aryl-3-Azabicyclo[3.1.0]Hexanes: Preparation And Use To Treat Neuropsychiatric Disorders | HTR3C, HTR1B, HTR2C | CYP4F2 573/4885CYP4A11 171/4885POLA1 3794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.